PPD Development LP
Wilmington, NC Doing business as PPD Development LP Part of Thermo Electron Corporation
- UEI
- ZANENSW6C665
- CAGE
- 3FAW2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
-
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) Primary
- 311999 All Other Miscellaneous Food Manufacturing
- 325413 In-Vitro Diagnostic Substance Manufacturing
- 518210 Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
- 541330 Engineering Services
- 541380 Testing Laboratories and Services
- 541511 Custom Computer Programming Services
- 541512 Computer Systems Design Services
Show all
- 541513 Computer Facilities Management Services
- 541519 Other Computer Related Services
- 541611 Administrative Management and General Management Consulting Services
- 541614 Process, Physical Distribution, and Logistics Consulting Services
- 541618 Other Management Consulting Services
- 541690 Other Scientific and Technical Consulting Services
- 541713 Research and Development in Nanotechnology
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 541720 Research and Development in the Social Sciences and Humanities
- 541990 All Other Professional, Scientific, and Technical Services
- 561422 Telemarketing Bureaus and Other Contact Centers
- 611430 Professional and Management Development Training
- 621511 Medical Laboratories
- 622110 General Medical and Surgical Hospitals
- Corporate family
-
-
Thermo Electron Corporation
Parent
GMXUXVDSNL89
-
PPD Development LP
ZANENSW6C665
- Evidera, Inc. FNLYKNL2A2K4
- PPD Global Central Labs LLC YPNJBDKDGJV7
-
PPD Development LP
ZANENSW6C665
-
Thermo Electron Corporation
Parent
GMXUXVDSNL89
- SAM.gov registration date
- Physical address
- 929 N Front St, Wilmington, NC 28401, USA
- Website
- ppd.com
- Founded
- 1985
- Employees
- 10K-50K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Task order award- phase i clinical trials for the development of neurotherapeutics- DTI-117 in healthy volunteers/SAD… | Office of Logisitics and Acquisition Operations | $2,016,831 | |
| Daids monitoring for 1 phase III study: A5300B/I2003B (phoenix) | National Institute of Allergy and Infectious Diseases | $3,092,829 | |
| Task ORDER75N95025F00001 TO4 blueprint medtech preparation of pre-submission support for pilot participant. | National Institute on Drug Abuse | $5,334 | |
| BAA-FY24C3CP5-understanding heterogeneity in preferences for clinical trial participation in diverse patient… | Food and Drug Administration | $1,299,218 | |
| Fdabaa-24-00123, REF # FY24C1EP6, cardiovascular-kidney-metabolic (CKM) syndrome patient-reported outcome (pro) burden… | Food and Drug Administration | $724,461 |
About PPD Development LP
PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific, delivers clinical trial management, regulatory affairs support, data management, biospecimen tracking, and laboratory services to federal agencies as a prime contractor (91% of recent awards) on unrestricted and large-business competitive procurements. The company, headquartered in Wilmington, North Carolina with primary operations in Cape Fear, competes across full-and-open federal competitions without set-aside designations, reflecting its status as a large business entity within Thermo Fisher's portfolio.
Customer concentration skews toward health-focused federal agencies. The National Institute of Allergy and Infectious Diseases dominates by award count (33 awards, $2.95 billion combined potential value), but the Defense Health Agency anchors dollar exposure with 5 awards carrying $10.91 billion in combined potential value, primarily through the OMNIBUS IV Military Medical Research and Development indefinite delivery contract ($10 billion ceiling awarded June 2022). The National Cancer Institute (6 awards, $824.1 million), the Office of the Assistant Secretary for Preparedness and Response (7 awards, $360.9 million), and the National Institute on Drug Abuse (14 awards, $84.1 million) round out the top five by potential value; these five customers account for 97% of PPD's combined potential value across all awards. Award count and dollar rankings diverge significantly—NIAID's volume dominates by count, but DHA's single large vehicle dwarfs it in dollars.
PPD sits on multiple strategically positioned parent vehicles. The OASIS+ Unrestricted GWAC (General Services Administration, awarded December 2024 with a multi-billion-dollar ceiling) enables task-order work across federal agencies government-wide. The $545.5 million Comprehensive and Rapid Response for NIAID Research Programs single-award IDIQ (September 2021 through August 2028) has generated multiple large delivery orders including a $186.4 million NIAID Clinical Site Monitoring contract (awarded February 2024), a $75.2 million HIV and infectious diseases clinical research support order (August 2024), and a $64 million ACTIV-2 COVID-19 study completion contract (November 2022). The $346.6 million Early Phase Clinical Trial Units (EPCTU) multiple-award vehicle with NIAID (January 2022 through January 2032) supports Phase 0–II trials across therapeutic areas. PPD also holds a $548 million Cancer Trials Support Unit multiple-award IDIQ with the National Cancer Institute (August 2022 through 2032), a $49.9 million Blueprint MedTech single-award IDIQ with NIDA (September 2023 through August 2028), and a $24 million Blueprint MedTech regulatory affairs single-award IDIQ with NIDA (September 2022 through September 2027). Recent concrete work includes a $222.1 million ASPR definitive contract for a Phase 2 ARDS clinical trial (December 2023), a $126.5 million ASPR vaccine immunogenicity contract (September 2023), and a $1.3 million FDA contract for patient preferences in clinical trial participation (September 2024).
Activity remains substantial but shows recent decline. Awards per year averaged 9 across 2022–2024 but dropped to 3 in 2025 and 1 in 2026 year-to-date; combined potential value across all 135 awards in the portfolio stands at $16.01 billion with $3.06 billion obligated (19%). Six awards with ultimate completion dates in the next twenty-four months carry combined potential value of $43.5 million and face recompete exposure. SCI-reported invoiced revenue on federal service contracts declined from $173.8 million in FY2022 to $77.5 million in FY2024, with federal FTE levels fluctuating (442 FTEs in FY2022, 363 FTEs in FY2024); across SCI-reportable prime contracts, median government-paid rates ran around $152/hr, with senior labor pricing extending through $213/hr. PPD self-performed the vast majority of work—subcontractors accounted for 3% of total contractor hours across SCI-reportable prime contracts, with 18 named subcontractors engaged over the SCI reporting period.
PPD operates as a prime contractor overwhelmingly; on subcontract work, the vendor provides clinical trial and vaccine development support to International Aids Vaccine Initiative (Marburg and Ebolavirus vaccine development sub-awards, December 2025) and FDA regulatory compliance training support to General Dynamics Information Technology (April 2024). The vendor also appears as a named sub-recipient on a Family Health International grant for DMPA XT work (NIAID, November 2023). The named subsidiary Evidera, Inc. carries capability signals around evidence and outcomes research, though specific subsidiary-level award attribution is not detailed in the source. The broader Thermo Fisher parent operates across life sciences manufacturing, diagnostics, and related federal contract vehicles, positioning PPD as the research-services arm of a diversified science and technology conglomerate.
Contract vehicles
- Cancer Trials Support Unit
- Early Phase Clinical Trial Units
- Omnibus IV Military Medical Research And Development
- One Acquisition Solution for Integrated Services Plus - Unrestricted
- CRO Support for NCATS Bioanalytical Method Development
- Medical Product Research and Development
- NIH Cancer Trials Support Unit
- Nonclinical Services for Development of Interventional Agents
Quick answers
What is PPD Development LP's UEI?
PPD Development LP's Unique Entity ID (UEI) in SAM.gov is ZANENSW6C665.
What is PPD Development LP's CAGE code?
PPD Development LP's CAGE code is 3FAW2.
What is PPD Development LP's primary NAICS code?
PPD Development LP's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is PPD Development LP located?
PPD Development LP's physical address in SAM.gov is 929 N Front St, Wilmington, NC 28401, USA.
Is PPD Development LP registered in SAM.gov?
Yes. PPD Development LP's SAM.gov registration is active through September 28, 2027.
Who is PPD Development LP's parent company?
PPD Development LP is part of Thermo Electron Corporation.
Which contract vehicles does PPD Development LP hold?
PPD Development LP holds a place on 8 federal contract vehicles, including Cancer Trials Support Unit, EPCTU and OMNIBUS IV.
What is PPD Development LP's most recent federal award?
PPD Development LP's most recent federal contract award is Task order award- phase i clinical trials for the development of neurotherapeutics- DTI-117 in healthy volunteers/SAD… (75N98026F00001), from Office of Logisitics and Acquisition Operations, on June 29, 2026.
On GovTribe
See PPD Development LP's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors